Kyung Nam Pharm has decided to conduct a rights offering of 11 million new shares through a shareholder allocation followed by a public offering of unsubscribed shares to secure 19.1 billion won in operating funds. The expected issue price for the new shares is 1,735 won, and the
2026-05-21
The 'CRKL/circCCDC50/NFATc1' signaling axis has been identified as a key mechanism underlying denosumab resistance, which occurs in approximately 40% of patients with breast cancer bone metastases. This signaling axis activates osteoclasts independently of RANKL, causing bone met
2026-05-21
Aprogen will issue 10 billion won in convertible bonds (CBs) to acquire securities of its pharmaceutical manufacturing subsidiary, Aprogen Biologics. The privately placed CBs will have a coupon rate of 2% and a maturity interest rate of 4%. The conversion price is set at 5,350 wo
2026-05-21
Hanmi Pharmaceutical has signed a 52.7 billion won supply agreement with Organon for three cardiovascular and respiratory treatments, entering the Philippine and Malaysian markets. The agreement includes an upfront payment of approximately $1.07 million and runs for 10 years from
2026-05-21
Eli Lilly’s next-generation obesity treatment produced weight loss of up to 28.3% in a late-stage clinical trial, but 11% of participants discontinued treatment because of adverse events. The phase 3 study followed patients with obesity or overweight who did not have diabetes for
2026-05-21
A Stanford University research team developed a “smart switch” technology that autonomously regulates CAR-T cell activity using a 15-amino-acid sequence. When a tumor antigen activates the cells, the ADAM17 enzyme cleaves a specific site, separating the CAR receptor and blocking
2026-05-21
Daewoong Pharmaceutical has secured exclusive global rights, excluding South Korea, to semaglutide, an obesity treatment administered once every 4 weeks. The long-acting injectable reduces dosing frequency by incorporating Tion Lab Therapeutics’ early-release-controlled depot for
2026-05-21
Eli Lilly’s next-generation obesity drug retatrutide produced an average weight loss of 28.3% after 80 weeks in a phase 3 trial. However, the discontinuation rate due to adverse events in the highest-dose group was 11%, higher than the up to 7% reported for existing treatments. O
2026-05-21
Eli Lilly’s next-generation obesity treatment retatrutide produced an average weight reduction of 28.3% after 80 weeks of treatment in a phase 3 trial. Although this approached the level seen with metabolic-bariatric surgery, the discontinuation rate due to adverse events reached
2026-05-21
Liminatus Pharma will acquire CAR-T biotech company InnosAI in an all-stock transaction valued at 464 billion won ($320 million). Under the agreement, Liminatus will issue 1.6 billion shares priced at 20 cents per share. The key pipeline asset is IBC101, a CAR-T therapy for B-cel
2026-05-21
